Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

HC Wainwright & Co. Downgrades Intercept Pharma to Neutral, Announces $19 Price Target

Author: Benzinga Newsdesk | September 27, 2023 06:44am
HC Wainwright & Co. analyst Ed Arce downgrades Intercept Pharma (NASDAQ:ICPT) from Buy to Neutral and announces $19 price target.

Posted In: ICPT

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist